Investigating how to reduce inflammation in glaucoma
Modulation of Neuroinflammation in Glaucoma
This study is looking at how inflammation in the brain affects glaucoma and aims to find ways to protect eye nerve cells by adjusting certain proteins, which could lead to new treatments for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11085974 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of neuroinflammation in glaucoma, a condition that can lead to blindness. The team will explore how specific proteins in the brain's support cells, called astrocytes, can be manipulated to reduce inflammation and protect nerve cells in the eye. By deleting certain proteins, they aim to prevent the harmful effects of inflammation on retinal cells, potentially leading to new treatments for glaucoma. The research involves both laboratory experiments and analysis of cellular responses to better understand these mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glaucoma, particularly those experiencing neuroinflammation-related symptoms.
Not a fit: Patients who do not have glaucoma or those with advanced stages of the disease where nerve damage is irreversible may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that protect vision in patients with glaucoma by reducing harmful inflammation.
How similar studies have performed: Previous studies have shown promising results in targeting neuroinflammation for neuroprotection in various conditions, suggesting potential success for this approach in glaucoma.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Tezel, Gulgun — Columbia University Health Sciences
- Study coordinator: Tezel, Gulgun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.